In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Insomnia is a significant health and quality of life concern for older adults, with up to half of all adults over the age of 65 experiencing insomnia symptoms.